newsfilter
← Latest News
Business Wire·

OSE Immunotherapeutics Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies

Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (PARIS:OSE) today provides a regulatory update on the clinical development plan of Tedopi®, an immunotherapy activating tumor specific